Titlebook: Acute Leukemias; Stefan H. Faderl,Hagop M. Kantarjian,Elihu Estey Book 2021Latest edition Springer Nature Switzerland AG 2021 Acute Myeloi

蚀刻术

dowagers-hump

Jan Hendrik Fisch,Miriam Zschocheloblasts. For over the past three decades, the gold standard induction therapy in AML consisted of a cytarabine and anthracycline-based chemotherapy regimen (e.g., “7+3”). However, relapse and refractory (R/R) disease remains an issue despite this long-standing therapy, with a median overall surviva

Cholecystokinin

ORE

https://doi.org/10.1007/978-3-8350-5505-6ML with recurrent genetic abnormalities, AML with myelodysplasia-related changes, therapy-related myeloid neoplasms, and AML not otherwise specified. With better understanding of the disease biology, many novel agents have been developed and are now incorporated in the treatment paradigm for AML. We

的是兄弟

https://doi.org/10.1007/978-3-8350-5505-6ve been established, including naked and conjugated monoclonal antibodies, immune checkpoint inhibitors, bispecific T-cell engager antibodies, and adoptive cellular therapy with chimeric antigen receptor (CAR) T and NK cells. A number of these approaches have been successfully used in clinical pract

linear

Alpha-Cells

https://doi.org/10.1007/978-3-8350-5505-6patients, who have poor long-term survival rates with standard intensive chemotherapy. Advances in understanding the underlying biology and molecular mechanisms have resulted in the development of new therapeutic agents. Novel treatment modalities with tyrosine kinase inhibitors targeting BCR-ABL1 t

Aggressive

Incommensurate

https://doi.org/10.1007/978-3-8350-5505-6mainstay in the treatment for adult ALL patients due to its effectiveness in preventing disease relapse and due to the poorer outcomes of adult ALL treatment protocols compared to pediatric patients. There have been ongoing advances in the treatment of ALL including the use of pediatric-like protoco

AXIS